🇺🇸 FDA
Pipeline program

177Lu-PSMA-617

19/195

Phase 2 small_molecule active

Quick answer

177Lu-PSMA-617 for Metastatic Hormone Naive Prostate Cancer is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Metastatic Hormone Naive Prostate Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials